COMP <GO>
GILD vs MRK // EV/EBITDA & P/E VALUATION
Gilead Sciences Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: GILD 9
— MRK 6
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
valuation
21.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GILD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GILD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.80% | 74.80% | +4.00 | GILD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | 20.70% | +0.30 | GILD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | 15.3x | +5.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 3.42% | +1.18 | GILD | /fcf-yield <GO> |
| Operating Margin | 34.00% | 34.30% | -0.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 28.90% | 28.10% | +0.80 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) | 2.40% | 1.30% | +1.10 | GILD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.95% | 2.26% | -0.31 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 5.19 | +0.68 | GILD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | GILD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | GILD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.3 | 56.9 | +17.42 | GILD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.92 | -0.04 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.4x | 18.4x | +4.00 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $205.35B | $361.02B | -$155.67B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GILD REV | MRK REV | GILD GROSS % | MRK GROSS % | GILD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | $65.01B | 78.8% | 74.8% | $9.46B | $12.36B |
| FY 2024 | $28.75B | $64.17B | 78.3% | 76.3% | $10.30B | $18.10B |
| FY 2023 | $27.12B | $60.12B | 44.0% | 44.0% | $6.79B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GILD // BETA 0.88
MRK // BETA 0.92